Cargando…

Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor

Intra-abdominal perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Although no effective therapies have been agreed upon, mTOR inhibitors are currently being investigated as a potential therapy for this extremely rare tumor. We present a case of a 64-year-old male found to h...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhlenhopp, Dustin J, West, Jacob, Heckart, Jonathan, Campbell, Ruth, Elhaddad, Abdelaziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104191/
https://www.ncbi.nlm.nih.gov/pubmed/32257249
http://dx.doi.org/10.1093/omcr/omaa013
_version_ 1783512189053698048
author Uhlenhopp, Dustin J
West, Jacob
Heckart, Jonathan
Campbell, Ruth
Elhaddad, Abdelaziz
author_facet Uhlenhopp, Dustin J
West, Jacob
Heckart, Jonathan
Campbell, Ruth
Elhaddad, Abdelaziz
author_sort Uhlenhopp, Dustin J
collection PubMed
description Intra-abdominal perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Although no effective therapies have been agreed upon, mTOR inhibitors are currently being investigated as a potential therapy for this extremely rare tumor. We present a case of a 64-year-old male found to have a large intra-abdominal PEComa with multiple metastatic lesions in the liver. Patient underwent surgical resection of the primary lesion in the abdomen and sigmoid colon followed by adjuvant therapy with the mTOR inhibitor, sirolimus. Initial response was noted with a decrease in size and number of lesions found in the patient’s liver. After 8 months of therapy, restaging imaging showed disease progression in the liver lesions. Patient subsequently failed treatments with pazopanib, investigational therapy TAK-228 (Sapanisertib) and nivolumab and ipilimumab. Overall the patient died after 22 months of disease. PEComas generally follow a benign course. This case is a much rarer entity given the malignant features/outcome.
format Online
Article
Text
id pubmed-7104191
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-71041912020-04-03 Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor Uhlenhopp, Dustin J West, Jacob Heckart, Jonathan Campbell, Ruth Elhaddad, Abdelaziz Oxf Med Case Reports Case Report Intra-abdominal perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Although no effective therapies have been agreed upon, mTOR inhibitors are currently being investigated as a potential therapy for this extremely rare tumor. We present a case of a 64-year-old male found to have a large intra-abdominal PEComa with multiple metastatic lesions in the liver. Patient underwent surgical resection of the primary lesion in the abdomen and sigmoid colon followed by adjuvant therapy with the mTOR inhibitor, sirolimus. Initial response was noted with a decrease in size and number of lesions found in the patient’s liver. After 8 months of therapy, restaging imaging showed disease progression in the liver lesions. Patient subsequently failed treatments with pazopanib, investigational therapy TAK-228 (Sapanisertib) and nivolumab and ipilimumab. Overall the patient died after 22 months of disease. PEComas generally follow a benign course. This case is a much rarer entity given the malignant features/outcome. Oxford University Press 2020-03-30 /pmc/articles/PMC7104191/ /pubmed/32257249 http://dx.doi.org/10.1093/omcr/omaa013 Text en © The Author(s) 2020. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Uhlenhopp, Dustin J
West, Jacob
Heckart, Jonathan
Campbell, Ruth
Elhaddad, Abdelaziz
Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title_full Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title_fullStr Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title_full_unstemmed Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title_short Rapidly enlarging malignant abdominal PEComa with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
title_sort rapidly enlarging malignant abdominal pecoma with hepatic metastasis: a promising initial response to sirolimus following surgical excision of primary tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104191/
https://www.ncbi.nlm.nih.gov/pubmed/32257249
http://dx.doi.org/10.1093/omcr/omaa013
work_keys_str_mv AT uhlenhoppdustinj rapidlyenlargingmalignantabdominalpecomawithhepaticmetastasisapromisinginitialresponsetosirolimusfollowingsurgicalexcisionofprimarytumor
AT westjacob rapidlyenlargingmalignantabdominalpecomawithhepaticmetastasisapromisinginitialresponsetosirolimusfollowingsurgicalexcisionofprimarytumor
AT heckartjonathan rapidlyenlargingmalignantabdominalpecomawithhepaticmetastasisapromisinginitialresponsetosirolimusfollowingsurgicalexcisionofprimarytumor
AT campbellruth rapidlyenlargingmalignantabdominalpecomawithhepaticmetastasisapromisinginitialresponsetosirolimusfollowingsurgicalexcisionofprimarytumor
AT elhaddadabdelaziz rapidlyenlargingmalignantabdominalpecomawithhepaticmetastasisapromisinginitialresponsetosirolimusfollowingsurgicalexcisionofprimarytumor